AbbVie Inc. (LON:0QCV)

Market Cap	294.19B
Revenue (ttm)	44.37B
Net Income (ttm)	1.75B
Shares Out	n/a
EPS (ttm)	0.98
PE Ratio	168.42
Forward PE	16.01
Dividend	5.03 (2.31%)
Ex-Dividend Date	Oct 15, 2025

Volume	1,992
Average Volume	4,342
Open	220.00
Previous Close	217.79
Day's Range	217.57 - 220.78
52-Week Range	159.76 - 244.49
Beta	0.35
RSI	43.72
Earnings Date	Oct 31, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 55,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QCV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD